-
Product Insights
NewSleep Apnea – Drugs In Development, 2024
Empower your strategies with our Sleep Apnea – Drugs In Development, 2024 report and make more profitable business decisions. Sleep apnea, a prevalent condition, involves the recurrent interruption and resumption of breathing during sleep. Two main types exist, obstructive and central sleep apnea. Obstructive sleep apnea occurs when the upper airway is frequently blocked, diminishing or halting airflow. Common risk factors include obesity, enlarged tonsils, and hormonal changes. Central sleep apnea results from the brain's failure to send necessary signals for...
-
Product Insights
NewBronchitis – Drugs In Development, 2024
Empower your strategies with our Bronchitis – Drugs In Development, 2024 report and make more profitable business decisions. Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked; shortness of breath aggravated by exertion or mild activity; frequent respiratory infections worsen symptoms; wheezing, fatigue, and headaches. Risk factors include smoking, older age and gastric reflux. The Bronchitis drugs in development market research...
-
Product Insights
NewMuscle Spasticity – Drugs In Development, 2024
Empower your strategies with our Muscle Spasticity – Drugs In Development, 2024 report and make more profitable business decisions. Muscle spasticity is a condition that causes muscles to contract, stiffen, or spasm involuntarily, affecting movement, speech, and gait. It is caused by damage or disruption to the nerve pathways that control muscle movement, usually due to brain or spinal cord injury, cerebral palsy, multiple sclerosis, or other diseases. Spasticity can range from mild to severe and can cause pain, deformity, fatigue,...
-
Product Insights
NewGeneralized Anxiety Disorder (GAD) – Drugs In Development, 2024
Empower your strategies with our Generalized Anxiety Disorder (GAD) – Drugs In Development, 2024 report and make more profitable business decisions. Generalized anxiety disorder is a mental health disorder that produces fear, worry, and a constant feeling of being overwhelmed. It is characterized by excessive, persistent, and unrealistic worry about everyday things. Individuals with GAD typically experience heightened anxiety and apprehension, anticipating negative outcomes in everyday situations. Physical symptoms may include restlessness, muscle tension, fatigue, and difficulty concentrating. Unlike specific phobias...
-
Product Insights
NewIrritable Bowel Syndrome – Drugs In Development, 2024
Empower your strategies with our Irritable Bowel Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects the large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite, and constipation. These symptoms can be triggered by food, stress, and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant, and antibiotic medications. The Irritable Bowel Syndrome drugs in...
-
Product Insights
NewSmoking Cessation – Drugs In Development, 2024
Empower your strategies with our Smoking Cessation – Drugs In Development, 2024 report and make more profitable business decisions. Smoking is addictive; smokers experience an uncontrollable dependence on cigarettes, and stopping can cause severe mental, emotional, or physical reactions. People addicted to smoking develop a tolerance to nicotine. Nicotine acts on acetylcholine receptors, causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological...
-
Product Insights
NewVitiligo – Drugs In Development, 2024
Empower your strategies with our Vitiligo – Drugs In Development, 2024 report and make more profitable business decisions. Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair, and eyes. Symptoms include premature whitening or graying of the hair on teh scalp, eyelashes, eyebrows, or beard; loss of color in the tissues that line the inside of mouth; and loss of or change in color of the inner layer of eye. Treatment includes...
-
Product Insights
NewOpium (Opioid) Addiction – Drugs In Development, 2024
Empower your strategies with our Opium (Opioid) Addiction – Drugs In Development, 2024 report and make more profitable business decisions. Opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers, known as endorphins). This can lead to an inability of the body to stop pain, because there are no endorphins to mask the pain initially. The degeneration...
-
Product Insights
NewTraumatic Brain Injury – Drugs In Development, 2024
Empower your strategies with our Traumatic Brain Injury – Drugs In Development, 2024 report and make more profitable business decisions. Traumatic brain injury (TBI) happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping, and memory or concentration problems. Risk factors include age. Certain types of traumatic brain injury increase the risk of developing...
-
Product Insights
NewKeratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...